Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Media

The FT, Sky News, Bloomberg, WSJ, along with over 77 other leading press organisations worldwide quote our data and insight and consider us a trusted, independent source.

Fiber will continue to dominate APAC fixed communication services market through 2030, forecasts GlobalData

Fixed communications service revenue in Asia-Pacific (APAC) is forecast to register a compound annual growth rate (CAGR) of 1% between 2025 and 2030. This growth will be supported by continued increases in fixed broadband subscriptions—particularly in the region’s emerging markets—and will be led by the fiber broadband segment, according to GlobalData, a leading data and […]
Read more

Indonesia to significantly enhance airlift and joint-operations capabilities with A400M Atlas induction, says GlobalData

Indonesia’s Air Force has recently received its first A400M Atlas tactical airlifter from Airbus, marking a major milestone in the country’s air mobility modernization program. The A400M significantly enhances Indonesia’s ability to transport personnel, heavy equipment, and humanitarian supplies across its vast archipelago, while also improving the nation’s capacity to engage in bilateral and multilateral […]
Read more

France renewable power capacity to reach 163.1GW in 2035, forecasts GlobalData

France is accelerating its clean energy transition, supported by expanding wind and solar deployment, modernization of hydropower, and strong government policy backing. The country’s cumulative renewable power capacity is forecast to reach 163.1GW by 2035, up from 59.1GW in 2024, registering a compound annual growth rate (CAGR) of 9.7% during 2024–35, according to GlobalData, a […]
Read more

Influencer discussions on AI bubble surge 200% on X as concerns grow over massive investments, reveals GlobalData

Discussions of the ‘AI Bubble’ among social media influencers surged in October 2025, increasing by almost 200% on platform ‘X’ compared to the previous month. This dramatic escalation was fueled by growing concerns over the sustainability of massive investments in AI versus its tangible returns, highlighting fears among influencers of an impending collapse similar to […]
Read more

Renewables to account for 73.3% of Australia’s power generation by 2035, forecasts GlobalData

Australia is undergoing a rapid energy transition, driven by strong government policies, abundant solar and wind resources, and ambitious net-zero targets. Renewables are forecast to account for 73.3% of the country’s total power generation by 2035, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, “Australia Power Market Trends and Analysis by […]
Read more

Eli Lilly and NVIDIA’s AI collaboration to reshape drug discovery landscape, says GlobalData

Eli Lilly and NVIDIA have recently announced a collaboration to build a new AI supercomputer dedicated to pharmaceutical research. The supercomputer will enable Eli Lilly to accelerate molecular simulations, analyze protein structures, and train large scale AI models for drug discovery and clinical research. By merging advanced AI with deep biological insight, the partnership is […]
Read more

Space manufacturing shows potential for next-generation therapies, says GlobalData

The space environment is rapidly emerging as a vital platform for scientific discovery and biomedical advancement. As space becomes more accessible, pharmaceutical and biotech companies are focusing on low-Earth orbit to explore new opportunities in drug development and disease modelling and therapeutic design, according to GlobalData, a leading data and analytics company. Microgravity affects biological […]
Read more

APAC equities steady in 2025 as AI boom and easing trade tensions support market sentiment, says GlobalData

Asia-Pacific equities remained resilient through 2025 as trade uncertainty, political shifts, and the rapid acceleration of artificial intelligence (AI) reshaped regional markets. The standout driver was a strong AI-led rise in technology and semiconductor stocks, helping cushion broader volatility. As 2026 approaches, contrasting monetary paths and renewed tariff risks point to another period of sharp […]
Read more

High-value deals drive venture capital activity amid overall slowdown during Q1-Q3 2025, reveals GlobalData

Global venture capital (VC) activity in Q1-Q3 2025 shows a clear shift in strategy as overall deal volume year-on-year (YoY) declined mainly due to an 11% drop in low-value (≤ $10 million) investments. However, high-value investments (>$100 million) rose 17% and billion-dollar deals volume also increased. This reflects investors’ focus on fewer but stronger opportunities […]
Read more

Magnificent 7 ramp-up R&D and capex as AI shift drives $2 trillion revenue surge, reveals GlobalData

The Magnificent 7—Apple, Microsoft, Alphabet, Amazon, Meta, NVIDIA, and Tesla—ended their latest fiscal year with an unmistakable theme: escalating R&D intensity and capital spending aligned around artificial intelligence (AI), even as cash balances normalize post-COVID-19 pandemic. The group collectively generated over $2.08 trillion in revenue, up about 14% year-on-year (YoY), underscoring the resilience of the […]
Read more

Sutaray NMPA approval marks major milestone in China HER2-positive breast cancer market, says GlobalData

The National Medical Products Administration (NMPA) in China has recently approved Sichuan Kelun Biotech Biopharmaceutical’s Sutaray (trastuzumab botidotin) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (BC). The move marks a pivotal advance in the nation’s oncology market as domestic innovation accelerates in high-need breast cancer segments, says GlobalData, a […]
Read more

Glaukos’ Epioxa to redefine treatment for keratoconus after a decade without new therapies, says GlobalData

FDA’s recent approval for Epioxa (IVMED-80) marks a landmark moment in ophthalmology, introducing the first and only incision-free, topical drug therapy for keratoconus. Developed by Glaukos Corporation, Epioxa is expected to transform keratoconus care from a procedure-based model to a pharmacologic one, emphasizing accessibility and patient comfort after nearly a decade without new treatment options, […]
Read more

Metsera takeover battle reflects Novo Nordisk and Pfizer push to challenge Lilly’s obesity drug dominance, says GlobalData

Following the news that Novo Nordisk made an unsolicited acquisition bid for US-based obesity biotech Metsera Therapeutics, which was subsequently rejected by Pfizer, but designated by Metsera as a “Superior Company Proposal” to the one previously agreed between Metsera and Pfizer: Jay Patel, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers […]
Read more
1 … 33 34 35 36 37 … 770